… Biostatistics, you will provide senior statistical leadership across clinical and translational programs. This is a hands-on, high-autonomy role with strong matrix leadership: you will shape quantitative strategy, guide study … move between hands-on analysis, study-level statistical leadership, and senior stakeholder discussion. You …
… Development team and to provide scientific and strategic leadership for the nonclinical safety assessment of our … as well as regulatory expectations. Provide scientific leadership for the design, execution, oversight, and … experience in nonclinical drug development, including leadership of toxicology programs supporting clinical …
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
